Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

21 janv. 2015 06h05 HE | Source: Curis, Inc.

Curis and Aurigene Announce Collaboration, License and Option Agreement to Discover, Develop and Commercialize Small Molecule Antagonists for Immuno-Oncology and Precision Oncology Targets

-- Agreement Provides Curis with Option to Exclusively License Aurigene's Antagonists for Immuno-Oncology, Including an Antagonist of PD-L1 and Selected Precision Oncology Targets, Including an...
18 déc. 2014 07h00 HE | Source: Curis, Inc.

Curis Announces Dosing of First Patient in Phase 1 Trial of CUDC-907 in Patients With Advanced/ Relapsed Solid Tumors

LEXINGTON, Mass., Dec. 18, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
26 nov. 2014 07h00 HE | Source: Curis, Inc.

Curis to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Nov. 26, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
12 nov. 2014 07h00 HE | Source: Curis, Inc.

Curis to Present at the Stifel 2014 Healthcare Conference

LEXINGTON, Mass., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
10 nov. 2014 07h00 HE | Source: Curis, Inc.

Curis Reports Third Quarter 2014 Financial Results and Pipeline Update

-- Curis Provides Summary From Dose Escalation Stage of CUDC-907 Phase 1 Study Supporting Ongoing Expansion in DLBCL Patients – -- Curis Expects to Regain Rights to Debio 0932; Debiopharm...
03 nov. 2014 07h00 HE | Source: Curis, Inc.

Curis to Release Third Quarter 2014 Financial Results and Hold Conference Call on November 10, 2014

LEXINGTON, Mass., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced that the...
28 oct. 2014 07h00 HE | Source: Curis, Inc.

Curis Announces Allowance of U.S. Patent Covering Compounds Targeting HDAC and PI3K Activities in a Single Molecule

LEXINGTON, Mass., Oct. 28, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
03 oct. 2014 07h00 HE | Source: Curis, Inc.

Curis to Present at the 13th Annual BIO Investor Forum

LEXINGTON, Mass., Oct. 3, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
02 oct. 2014 07h00 HE | Source: Curis, Inc.

Curis Announces CUDC-907 Development Program Advancements

-- Expansion cohorts opened to enroll patients with relapsed/refractory Diffuse Large B-Cell Lymphoma and Multiple Myeloma -- -- Second IND open for Curis to initiate additional clinical study in...
27 août 2014 07h00 HE | Source: Curis, Inc.

Curis to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...

Page précédente